NCT01767493

Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients

An Open-label, Non-randomized Study to Evaluate the Feasibility of [18F]Florbetapir Positron Emission Tomography (PET) for Assessment of Demyelination in Patients With Relapsing Remitting Multiple Sclerosis

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 19 (actual)
• Sponsor: Institute for Neurodegenerative Disorders · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the feasibility of \[18F\]Florbetapir positron emission tomography (PET) for assessment of demyelination in the patients with relapsing remitting multiple sclerosis.

Detailed description

The underlying goal of this study is to assess the feasibility of \[18F\]Florbetapir as an imaging tool to detect demyelination in the brain of MS research participants and compare to similarly aged healthy subjects.

Conditions

• Multiple Sclerosis

Interventions

Type	Name	Description
DRUG	[18F]Florbetapir PET imaging	\[18F\]Florbetapir and PET imaging

Timeline

• Start date: 2012-11-01
• Primary completion: 2013-11-01
• Completion: 2013-11-01
• First posted: 2013-01-14
• Last updated: 2021-08-30
• Results posted: 2021-08-27

Locations

1 site across 1 country: United States